Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MDH1 | P40925 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539586 | 0.88 | ALPI (0.59) | MAPTTP53TSHRNPC1RAB9A | |
| SCHEMBL7370822 | 0.87 | MAPT (0.49) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL7424382 | 0.82 | MAPT (0.64) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL7171003 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL3051371 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL302596 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL12113908 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL3052051 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL21908583 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 | |
| SCHEMBL3055019 | 0.81 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-0941236-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998023637-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193560-A1 | CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY | NGLY1, CHIT1, MANBA | MAPT 3196/4885TP53 3997/4885TSHR 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.